ZA965609B - Controlled release formulations for poorly soluble drugs - Google Patents

Controlled release formulations for poorly soluble drugs

Info

Publication number
ZA965609B
ZA965609B ZA965609A ZA965609A ZA965609B ZA 965609 B ZA965609 B ZA 965609B ZA 965609 A ZA965609 A ZA 965609A ZA 965609 A ZA965609 A ZA 965609A ZA 965609 B ZA965609 B ZA 965609B
Authority
ZA
South Africa
Prior art keywords
core
controlled release
poorly soluble
formulation
tablets
Prior art date
Application number
ZA965609A
Other languages
English (en)
Inventor
Maurice Joseph Anthony Clancy
Kenneth Iain Cumming
Michael Myers
Original Assignee
Elan Corp Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Corp Plc filed Critical Elan Corp Plc
Publication of ZA965609B publication Critical patent/ZA965609B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA965609A 1995-07-03 1996-07-02 Controlled release formulations for poorly soluble drugs ZA965609B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IE950492A IE80467B1 (en) 1995-07-03 1995-07-03 Controlled release formulations for poorly soluble drugs
US89795P 1995-07-06 1995-07-06
PCT/IE1996/000039 WO1997002017A1 (en) 1995-07-03 1996-07-01 Controlled release formulations for poorly soluble drugs

Publications (1)

Publication Number Publication Date
ZA965609B true ZA965609B (en) 1997-01-27

Family

ID=26319833

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA965609A ZA965609B (en) 1995-07-03 1996-07-02 Controlled release formulations for poorly soluble drugs

Country Status (20)

Country Link
EP (1) EP0836475B1 (no)
JP (1) JPH11508587A (no)
KR (1) KR19990028693A (no)
AT (1) ATE208192T1 (no)
AU (1) AU700654B2 (no)
BG (1) BG102228A (no)
BR (1) BR9609663A (no)
CA (1) CA2226008A1 (no)
CZ (1) CZ413497A3 (no)
DE (1) DE69616795T2 (no)
HU (1) HUP9900231A2 (no)
IE (1) IE80467B1 (no)
IL (1) IL122663A0 (no)
NO (1) NO975872L (no)
NZ (1) NZ311145A (no)
PL (1) PL324402A1 (no)
SK (1) SK175997A3 (no)
TW (1) TW426528B (no)
WO (1) WO1997002017A1 (no)
ZA (1) ZA965609B (no)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283029B1 (it) * 1996-05-17 1998-04-03 Resa Farma Composizioni farmaceutiche a base di diclofenac
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US6126970A (en) * 1995-12-01 2000-10-03 Janssen Pharmaceutica N.V. Cisapride sustained release
EP0951278A2 (en) * 1997-01-03 1999-10-27 ELAN CORPORATION, Plc Sustained release cisapride mini-tablet formulation
DE19710009A1 (de) * 1997-03-12 1998-09-24 Knoll Ag Mehrphasige wirkstoffhaltige Zubereitungsformen
US6312724B1 (en) 1997-04-04 2001-11-06 Isa Odidi Sustained release pharmaceutical matrix tablet of pharmaceutically acceptable salts of diclofenac and process for preparation thereof
NZ328751A (en) * 1997-09-16 1999-01-28 Bernard Charles Sherman Solid medicament containing an anionic surfactant and cyclosporin
US6013280A (en) * 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
AU9587198A (en) * 1997-10-07 1999-04-27 Fuisz Technologies Ltd. Immediate release drug delivery forms
NZ333474A (en) * 1998-01-02 1999-06-29 Mcneil Ppc Inc A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
IE980115A1 (en) * 1998-02-16 2000-02-09 Biovail Internat Ltd Solubilizing delivery systems and method of manufacture
US6787157B1 (en) 1998-03-10 2004-09-07 Abbott Laboratories Multiphase active ingredient-containing formulations
AU4679999A (en) * 1998-06-11 1999-12-30 Em Industries, Inc. Micro-osmotic controlled drug delivery systems
TW407058B (en) * 1998-07-17 2000-10-01 Dev Center Biotechnology Oral cisapride dosage forms with an extended duration
IE981008A1 (en) * 1998-12-02 2000-06-14 Fuisz Internat Ltd Microparticles Containing Water Insoluble Active Agents
ATE404178T1 (de) * 1999-02-10 2008-08-15 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter wirkstofffreisetzung
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
SE9902742D0 (sv) * 1999-07-20 1999-07-20 Astra Ab New pharmaceutical formultion
KR100379299B1 (ko) * 2000-01-15 2003-04-10 주식회사 중외제약 펠로디핀의 가용화 방법 및 방출제어형 제제
EP1390063B1 (en) * 2001-05-03 2004-11-17 F. Hoffmann-La Roche Ag Pharmaceutical dosage form of amorphous nelfinavir mesylate
AR033711A1 (es) * 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
TWI252111B (en) * 2001-12-14 2006-04-01 Solvay Pharm Gmbh Matrix film tablet with controlled release of a natural mixture of conjugated estrogens
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
KR20040011248A (ko) * 2002-07-30 2004-02-05 환인제약 주식회사 암로디핀의 고체분산체와 그 제조방법 및 그를 포함하는약학적 조성물
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
AU2003230189A1 (en) * 2003-01-29 2004-08-23 Nitin Bhalachandra Dharmadhikari Oral controlled release pharmaceutical composition containing metaxalone as active agent
EP1592760A4 (en) 2003-01-31 2009-08-12 Smithkline Beecham Corp AS FIXED DISPERSIONS, COMPOSITIONS
ES2665464T3 (es) * 2003-03-28 2018-04-25 Sigmoid Pharma Limited Forma de dosificación oral sólida que contiene microcápsulas sin costuras
MXPA06005461A (es) * 2003-11-13 2006-12-15 Johnson & Johnson Dispersiones de mezclas en estado fundido que comprenden un farmaco de baja solubilidad en agua y un copolimero de bloque de oxido de etileno-oxido de propileno.
WO2005065653A1 (en) * 2003-12-19 2005-07-21 E.I. Du Pont De Nemours And Company Intimate coating of ibuprofen with poloxamers to enhance aqueous dissolution
JP2007517016A (ja) 2003-12-31 2007-06-28 ファイザー・プロダクツ・インク 低溶解性薬剤及びポロキサマーの固体組成物
KR100598326B1 (ko) 2004-04-10 2006-07-10 한미약품 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
WO2007069874A1 (en) * 2005-12-16 2007-06-21 Hanmi Pharm. Co., Ltd. Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same
PT2054040E (pt) 2006-08-16 2011-06-30 Novartis Ag Método para produzir dispersões sólidas de compostos terapêuticos altamente cristalinos
US20100136111A1 (en) * 2007-03-30 2010-06-03 Ramakant Gundu Pharmaceutical compositions of diclofenac and misoprostol
EP2066309B1 (en) 2007-04-04 2012-08-29 Sigmoid Pharma Limited An oral pharmaceutical composition
EP2061587A1 (en) 2007-04-26 2009-05-27 Sigmoid Pharma Limited Manufacture of multiple minicapsules
AP2015008933A0 (en) 2009-04-24 2015-12-31 Iceutica Pty Ltd A novel formulation of diclofenac
CA2762179A1 (en) 2009-05-18 2010-11-25 Sigmoid Pharma Limited Composition comprising oil drops
CN107582526A (zh) 2009-08-12 2018-01-16 希格默伊德药业有限公司 包含聚合物基质和油相的免疫调节组合物
FR2967577B1 (fr) * 2010-11-18 2013-07-12 Advicenne Pharma Composition pharmaceutique comprenant du sel de bicarbonate, et son utilisation comme medicament
FR2967576B1 (fr) * 2010-11-18 2013-07-12 Advicenne Pharma Composition pharmaceutique comprenant du sel precurseur du cycle de krebs, en particulier du sel de citrate, et son utilisation comme medicament
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
DE102012105512A1 (de) * 2012-06-25 2014-04-24 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur verlängerten Freisetzung von Wirkstoffen
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
CN102784128B (zh) * 2012-07-31 2015-01-07 北京协和药厂 一种非洛地平缓释制剂及其制备方法
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
AU2015341695B2 (en) 2014-11-07 2021-07-08 Sublimity Therapeutics Limited Compositions comprising cyclosporin
CN112118830B (zh) * 2018-05-14 2023-11-10 比利时胶囊公司 高活性剂载量的固体剂型

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE76292T1 (de) * 1987-11-25 1992-06-15 American Cyanamid Co System fuer die verzoegerte (kontrollierte) freisetzung von substituierten dihydropyridincalciumantagonisten.

Also Published As

Publication number Publication date
DE69616795D1 (de) 2001-12-13
EP0836475B1 (en) 2001-11-07
EP0836475A1 (en) 1998-04-22
CA2226008A1 (en) 1997-01-23
ATE208192T1 (de) 2001-11-15
WO1997002017A1 (en) 1997-01-23
CZ413497A3 (cs) 1998-04-15
SK175997A3 (en) 1998-06-03
PL324402A1 (en) 1998-05-25
NZ311145A (en) 1999-06-29
NO975872L (no) 1998-03-03
KR19990028693A (ko) 1999-04-15
BG102228A (en) 1998-10-30
TW426528B (en) 2001-03-21
HUP9900231A2 (hu) 1999-06-28
AU700654B2 (en) 1999-01-14
DE69616795T2 (de) 2002-08-08
IL122663A0 (en) 1998-08-16
BR9609663A (pt) 1999-05-18
NO975872D0 (no) 1997-12-12
JPH11508587A (ja) 1999-07-27
MX9710413A (es) 1998-07-31
IE80467B1 (en) 1998-07-29
AU6239496A (en) 1997-02-05

Similar Documents

Publication Publication Date Title
IL122663A0 (en) Controlled release formulations for poorly soluble drugs
CA2232450A1 (en) Oral pharmaceutical composition containing antimicrobial actives and sustained release pantoprazole
AU1351788A (en) Slow-release pharmaceutical agent
MY100721A (en) Therapeutic agent.
UA29563C2 (uk) Мікрокапсула для тривалого вивільнення фізіологічно активного пептиду
AU4121297A (en) Galenic form with extended release of milnacipran
PT923934E (pt) Formulacao de matriz de libertacao modificada de cefaclor e cefalexina
CA2330480A1 (en) Controlled release formulation of divalproex sodium
UA66812C2 (uk) Препаративна форма лікарського засобу із регульованим вивільненням активної речовини
AU4903700A (en) Chronotherapeutic diltiazem formulations and the administration thereof
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
CA2000932A1 (en) Oral pharmaceutical controlled release multiple unit dosage form
HK1043945A1 (en) Pharmaceutical capsule compositions containing loratadine and pseudoephedrine.
DK1255535T3 (da) Lægemiddelsammensætning med kontrolleret frisætning indeholdende tramadol-hydrochlorid
EP0979649A3 (de) Verwendung von N-Vinylprrolidon-und Vinylacetat-haltigen Copolymeren als Matrix zur Herstellung von festen, oralen, pharmazeutischen und kosmetischen Zubereitungen
CA2307547A1 (en) Chronotherapeutic diltiazem formulations and the administration thereof
IL122719A (en) Controlled release pharmaceutical dosage forms for oral administration containing nifedipine as active substance and process for their preparation
MY114610A (en) Controlled drug delivery system for diltiazem.